Go Pro
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CG Oncology, Inc. stock logo
CGON
CG Oncology
$74.67
$73.63
$29.85
▼
$80.97
$6.62B0.24691,996 shs282,520 shs
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
$30.06
$29.74
$2.45
▼
$38.33
$1.86B1.46304,329 shs295,831 shs
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
$100.90
$109.09
$63.23
▼
$130.00
$6.55B0.49512,952 shs350,960 shs
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
$55.33
$53.44
$27.07
▼
$61.76
$6.74B0.671.02 million shs658,041 shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CG Oncology, Inc. stock logo
CGON
CG Oncology
0.00%+0.44%-0.57%+37.26%+125.79%
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
0.00%+3.66%+0.47%+43.76%+910.42%
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
0.00%+3.53%+0.25%+7.82%+32.66%
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
0.00%-4.27%+4.55%+26.32%+76.15%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CG Oncology, Inc. stock logo
CGON
CG Oncology
$74.67
$73.63
$29.85
▼
$80.97
$6.62B0.24691,996 shs282,520 shs
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
$30.06
$29.74
$2.45
▼
$38.33
$1.86B1.46304,329 shs295,831 shs
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
$100.90
$109.09
$63.23
▼
$130.00
$6.55B0.49512,952 shs350,960 shs
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
$55.33
$53.44
$27.07
▼
$61.76
$6.74B0.671.02 million shs658,041 shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CG Oncology, Inc. stock logo
CGON
CG Oncology
0.00%+0.44%-0.57%+37.26%+125.79%
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
0.00%+3.66%+0.47%+43.76%+910.42%
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
0.00%+3.53%+0.25%+7.82%+32.66%
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
0.00%-4.27%+4.55%+26.32%+76.15%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CG Oncology, Inc. stock logo
CGON
CG Oncology
2.77
Moderate Buy$83.1811.40% Upside
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
3.00
Buy$44.0046.37% Upside
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
2.93
Moderate Buy$137.3136.09% Upside
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
3.13
Buy$58.776.22% Upside

Current Analyst Ratings Breakdown

Latest DMRA, SRRK, CGON, and MIRM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/27/2026
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$137.00
8/27/2026
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform
8/27/2026
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
Citizens Jmp logo
Citizens Jmp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform$137.00
8/24/2026
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
8/21/2026
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$64.00
8/13/2026
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$56.00 ➝ $63.00
8/10/2026
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$65.00
8/10/2026
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$58.00
8/7/2026
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$76.00
8/7/2026
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$58.00 ➝ $60.00
8/7/2026
CG Oncology, Inc. stock logo
CGON
CG Oncology
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$81.00 ➝ $79.00
(Data available from 9/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CG Oncology, Inc. stock logo
CGON
CG Oncology
$4.04M1,638.30N/AN/A$9.33 per share8.00
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
N/AN/AN/AN/A($110.11) per shareN/A
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
$521.31M12.57$0.05 per share1,979.24$6.12 per share16.49
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
N/AN/AN/AN/A$2.41 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CG Oncology, Inc. stock logo
CGON
CG Oncology
-$160.99M-$2.69N/AN/AN/A-3,602.68%-25.20%-23.98%11/13/2026 (Estimated)
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
-$209.84M-$3.37N/AN/AN/AN/A-176.39%-77.86%N/A
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
-$23.36M-$14.55N/AN/AN/A-139.18%-36.28%-8.54%11/3/2026 (Estimated)
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
-$377.94M-$3.45N/AN/AN/AN/A-160.19%-87.18%11/13/2026 (Estimated)

Latest DMRA, SRRK, CGON, and MIRM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/10/2026Q2 2026
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
-$0.4470-$0.39+$0.0570-$0.39N/AN/A
8/6/2026Q2 2026
CG Oncology, Inc. stock logo
CGON
CG Oncology
-$0.6642-$0.90-$0.2359-$0.90$0.36 million$1.16 million
8/6/2026Q2 2026
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
-$0.8405-$0.84+$0.0005-$0.84$3.33 millionN/A
8/5/2026Q2 2026
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
-$0.7425-$1.06-$0.3175-$1.06$166.33 million$176.24 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
CG Oncology, Inc. stock logo
CGON
CG Oncology
N/AN/AN/AN/AN/A
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
N/AN/AN/AN/AN/A
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
N/AN/AN/AN/AN/A
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CG Oncology, Inc. stock logo
CGON
CG Oncology
N/A
22.22
22.20
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
N/A
19.73
19.73
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
1.28
2.86
2.74
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
0.77
7.02
7.02

Institutional Ownership

CompanyInstitutional Ownership
CG Oncology, Inc. stock logo
CGON
CG Oncology
26.56%
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
14.20%
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
N/A
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
91.08%

Insider Ownership

CompanyInsider Ownership
CG Oncology, Inc. stock logo
CGON
CG Oncology
4.80%
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
0.40%
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
8.32%
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
10.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
CG Oncology, Inc. stock logo
CGON
CG Oncology
6188.64 million84.39 millionOptionable
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
4061.74 million61.49 millionNo Data
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
14064.93 million59.53 millionOptionable
Scholar Rock Holding Corporation stock logo
SRRK
Scholar Rock
140121.79 million109.24 millionOptionable

Recent News About These Companies

Scholar Rock: Manufacturing Noise Obscures A Muscle-Targeted Franchise
 |  seekingalpha.comhttps://seekingalpha.com/article/4943566-scholar-rock-stock-manufacturing-noise-obscures-muscle-targeted-franchise
Legal & General Group Plc Invests $3.36 Million in Scholar Rock Holding Corporation $SRRK
September 5 at 4:07 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-legal-general-group-plc-invests-336-million-in-scholar-rock-holding-corporation-srrk-2026-09-05/
Scholar Rock Gets FDA Fast Track, Orphan Drug Designations for Muscular Disorder Drug
September 2, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/scholar-rock-gets-fda-fast-122353130.html
Senator Investment Group LP Acquires New Stake in Scholar Rock Holding Corporation $SRRK
August 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-senator-investment-group-lp-acquires-new-stake-in-scholar-rock-holding-corporation-srrk-2026-08-31/
122,223 Shares in Scholar Rock Holding Corporation $SRRK Acquired by The Manufacturers Life Insurance Company
August 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-122223-shares-in-scholar-rock-holding-corporation-srrk-acquired-by-the-manufacturers-life-insurance-company-2026-08-31/
Beaconlight Capital LLC Makes New Investment in Scholar Rock Holding Corporation $SRRK
August 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-beaconlight-capital-llc-makes-new-investment-in-scholar-rock-holding-corporation-srrk-2026-08-31/
Bank of New York Mellon Corp Acquires New Shares in Scholar Rock Holding Corporation $SRRK
August 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-new-york-mellon-corp-acquires-new-shares-in-scholar-rock-holding-corporation-srrk-2026-08-31/
104,346 Shares in Scholar Rock Holding Corporation $SRRK Acquired by Man Group plc
August 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-104346-shares-in-scholar-rock-holding-corporation-srrk-acquired-by-man-group-plc-2026-08-30/
Algert Global LLC Grows Stock Holdings in Scholar Rock Holding Corporation $SRRK
August 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-algert-global-llc-grows-stock-holdings-in-scholar-rock-holding-corporation-srrk-2026-08-29/
Jupiter Topco LLC Invests $123.28 Million in Scholar Rock Holding Corporation $SRRK
August 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-jupiter-topco-llc-invests-12328-million-in-scholar-rock-holding-corporation-srrk-2026-08-27/
96,285 Shares in Scholar Rock Holding Corporation $SRRK Acquired by Artia Global Partners LP
August 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-96285-shares-in-scholar-rock-holding-corporation-srrk-acquired-by-artia-global-partners-lp-2026-08-27/
Scholar Rock (NASDAQ:SRRK) Shares Up 5.8% - Still a Buy?
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-scholar-rock-nasdaq-srrk-shares-up-58-still-a-buy-2026-08-26/
EFG International AG Takes Position in Scholar Rock Holding Corporation $SRRK
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-efg-international-ag-takes-position-in-scholar-rock-holding-corporation-srrk-2026-08-26/
Nicholas Investment Partners LP Purchases New Position in Scholar Rock Holding Corporation $SRRK
August 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-nicholas-investment-partners-lp-purchases-new-position-in-scholar-rock-holding-corporation-srrk-2026-08-25/
9,494,084 Shares in Scholar Rock Holding Corporation $SRRK Purchased by BlackRock Inc.
August 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-9494084-shares-in-scholar-rock-holding-corporation-srrk-purchased-by-blackrock-inc-2026-08-25/
Scholar Rock (NASDAQ:SRRK) Sets New 52-Week High - Should You Buy?
August 24, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/scholar-rock-nasdaqsrrk-sets-new-52-week-high-should-you-buy-2026-08-24/
303,268 Shares in Scholar Rock Holding Corporation $SRRK Bought by Deutsche Bank AG
August 23, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-303268-shares-in-scholar-rock-holding-corporation-srrk-bought-by-deutsche-bank-ag-2026-08-23/
Scholar Rock (SRRK) Streamlines Apitegromab Filings After Catalent Shift Is Regulatory Strategy De-Risking The Story?
August 22, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/scholar-rock-srrk-streamlines-apitegromab-080945330.html
Scholar Rock (NASDAQ:SRRK): Healthcare Milestone Draws Focus
August 21, 2026  |  kalkinemedia.comK
Scholar Rock Removes Catalent Indiana From Apitegromab BLA as Fill-Finish Facility
August 21, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/scholar-rock-removes-catalent-indiana-133515854.html
Scholar Rock withdraws Europe filing for muscle weakness drug, plans resubmission
August 21, 2026  |  msn.comhttps://www.msn.com/en-us/money/markets/scholar-rock-withdraws-europe-filing-for-muscle-weakness-drug-plans-resubmission/ar-AA2aEmxz

New MarketBeat Followers Over Time

Media Sentiment Over Time

CG Oncology stock logo

CG Oncology NASDAQ:CGON

$74.67 0.00 (0.00%)
As of 09/4/2026 04:00 PM Eastern

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Damora Therapeutics, Inc. Common Stock stock logo

Damora Therapeutics, Inc. Common Stock NASDAQ:DMRA

$30.06 0.00 (0.00%)
As of 09/4/2026 04:00 PM Eastern

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

Mirum Pharmaceuticals stock logo

Mirum Pharmaceuticals NASDAQ:MIRM

$100.90 0.00 (0.00%)
As of 09/4/2026 04:00 PM Eastern

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Scholar Rock stock logo

Scholar Rock NASDAQ:SRRK

$55.33 0.00 (0.00%)
As of 09/4/2026 04:00 PM Eastern

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas